A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #366

[Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data].

Khavinson VKh, Kuznik BI, Tarnovskaia SI, et al. Advances in gerontology = Uspekhi gerontologii. 2014.
PubMed: 25826983
Weak / noneReviewMentions: Epitalon

Editor's note

This is a narrative review paired with the authors' own data, proposing that the short peptides vilon and epitalon influence the expression of two genes — CCL11 (eotaxin) and HMGB1 — that serve as molecular markers of ageing and of neurological, cardiovascular, and immune disease. The authors frame the peptides' geroprotective action as possible suppression of these genes. As a review, it synthesises and hypothesises rather than tests; the mechanistic claim here is a proposal, not a demonstrated causal pathway, and the abstract's phrasing about mortality reduction reflects the source literature's claims rather than new controlled evidence. This comes from the St. Petersburg institute that originated epitalon, so it should be read as an internally consistent hypothesis-building piece from a single research lineage with limited independent replication. It is useful for understanding the proposed mechanism, not as proof of a human benefit. Human data are needed before clinical conclusions can be drawn.

Plain-language abstract

This is a review article that also presents the authors' own findings. It focuses on two signalling proteins in the body — CCL11 (also called eotaxin) and HMGB1 — whose levels are used as markers of ageing and of nerve, heart, and immune-system disease. The authors, from the St. Petersburg institute that developed these peptides, describe how two short peptides, vilon and epitalon, may act on the genes that produce these two markers. They propose that the peptides' anti-ageing effects may work by turning down the activity of these genes. Because this is a review combining existing literature with the group's own data, it is presenting a proposed explanation rather than proving cause and effect. The article does not report a controlled trial or side-effect data, and the ideas it puts forward would need testing in well-designed human studies before any conclusions could be drawn.